Candel Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Candel Therapeutics (NASDAQ: CADL), a clinical stage biopharmaceutical company developing biological immunotherapies for cancer treatment, has announced its participation in two major upcoming investor conferences:

1. Bank of America Securities 2025 Health Care Conference in Las Vegas: - Chief Scientific Officer Francesca Barone will present on May 14, 2025, at 4:20 PM PT - Location: Las Vegas, NV

2. Jefferies Global Healthcare Conference in New York: - President and CEO Paul Peter Tak will present on June 5, 2025, at 8:40 AM PT - Location: New York, NY

Live webcasts will be available on Candel's website under the Investors section, with replays archived for up to 90 days after the presentations.

NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today that management will present and participate in one-on-one meetings with investors at upcoming investor conferences.                                                 

Bank of America Securities 2025 Health Care Conference (Las Vegas, NV)
Presenter: Francesca Barone, MD, PhD, Candel’s Chief Scientific Officer
Date/Time: Wednesday, May 14, 2025, at 4:20 PM PT / 7:20 PM ET
Webcast Link: Bank of America / Candel Presentation

Jefferies Global Healthcare Conference (New York, NY)
Presenter: Paul Peter Tak, MD, PhD, FMedSci, Candel’s President and Chief Executive Officer
Date/ Time: Thursday, June 5, 2025, at 8:40 AM PT / 11:40 AM ET
Webcast Link: Jefferies / Candel Presentation

Live webcasts of the presentations will be available by selecting Events and Presentations under the News & Events tab in the Investors section on www.candeltx.com. A replay of the webcasts will be archived for up to 90 days following the session date.

About Candel Therapeutics

Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 (aglatimagene besadenovec) is the lead product candidate from the adenovirus platform and recently completed successful phase 2a clinical trials in non-small cell lung cancer and borderline resectable pancreatic ductal adenocarcinoma, and a pivotal phase 3 clinical trial in localized prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

For more information about Candel, visit: www.candeltx.com.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; and expectations regarding the therapeutic benefit of the Company’s platforms. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report on Form 10-K filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Investor Contact
Theodore Jenkins
Vice President, Investor Relations, and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com

Media Contact
Ben Shannon
Vice President
ICR Healthcare
CandelPR@icrhealthcare.com

FAQ

When is Candel Therapeutics (CADL) presenting at the Bank of America Healthcare Conference 2025?

Candel Therapeutics will present at the Bank of America Healthcare Conference on Wednesday, May 14, 2025, at 4:20 PM PT / 7:20 PM ET in Las Vegas.

Who will represent Candel Therapeutics (CADL) at the Jefferies Global Healthcare Conference 2025?

Paul Peter Tak, MD, PhD, FMedSci, Candel's President and Chief Executive Officer, will represent the company at the Jefferies Global Healthcare Conference.

How can investors access Candel Therapeutics' (CADL) conference presentations?

Investors can access live webcasts through Candel's website (www.candeltx.com) under the Events and Presentations section in the Investors tab. Replays will be available for 90 days after the presentations.

What type of company is Candel Therapeutics (CADL)?

Candel Therapeutics is a clinical stage biopharmaceutical company that focuses on developing multimodal biological immunotherapies to help patients fight cancer.